Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025
ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that its management will participate in the Leerink Partners Global Healthcare Conference 2025, taking place from March 10-12, 2025, at the W South Beach Hotel in Miami, FL. Details are as follows:
| Format: | Fireside Chat |
| Representative: | Berndt Modig, CEO of Pharvaris |
| Date & Time: | Monday, March 10, 9:20 a.m. ET |
A live audio webcast will also be available on the Investors section of the Pharvaris website at: . The audio replay will be available on Pharvaris’ website for 30 days following the presentation.
About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy and placebo-like tolerability with the convenience of an oral therapy to prevent and treat HAE attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit .
Contact Maggie Beller Executive Director, Head of Corporate and Investor Communications
